1-855-378-42281-855-378-4228
One of the out-patient rehabilitation options for clients in Kleinfeltersville battling with opioid dependence and addiction is opioid maintenance therapy. Some facilities and doctors are certified to administer certain meds to opioid addicted individuals, many of which are opioid-based themselves and are addiction. With low doses however, the client doesn't feel high and also doesn't experience intense cravings and is not experiencing opioid withdrawal. Methadone is the first medication tried for this sole purpose, but there are alternative choices to choose from.
Methadone is an opioid and is meant to be taken at an out-patient medical center certified to dispense the med, which is taken on a daily basis as a pill or liquid. The cost of the med is about $150 a month. Buprenorphine is also an opiate based drug, and is a pill often taken every other day. But different from Methadone which can only be administered in highly well-regulated medical centers, Buprenorphine can be and is prescribed and administered in doctor's offices. The monthly cost of buprenorphine is around $300.00 a month for the generic version of the med. There is also a version of buprenorphine containing the drug naloxone, which is a med that reverses the effects of opioids. Someone taking this version of the drug, also known as Suboxone, would find it more difficult to feel high from opioids if they relapsed while taking the drug. It too is taken on a daily basis, and costs about $450 /month. Naltrexone is another med taken in opioid maintenance therapy, but unlike the other medications mentioned it is an opiate blocker and isn't an opioid. A person has the choice to take this medication as a monthly injection, and that is called Vivitrol. As an opioid blocker, it prevents someone from experience high feelings from opioids, and in turn lowers the risk associated with relapse. This daily injection costs in the range of $1000 to $1200 monthly.
For All Alcohol and Drug Rehab Programs In Kleinfeltersville, Click Here.
